Read More Pharma Industry News Jagsonpal Pharmaceuticals Q1 FY26 results: Can sustained brand momentum and strong cash flows drive further growth in India’s domestic market? Jagsonpal Pharmaceuticals’ Q1 FY26 revenue rose 23% YoY to ₹756M, with PAT doubling to ₹108M. Can strong cash flows fuel future inorganic growth? byPallavi MadhirajuJuly 27, 2025